ORIGINAL RESEARCH

# SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer

Ying Lv,[1,*] Xin Wang,[2,3,*]
Lerong Liang,[4] Lei Wang,[5]
Jie Lu[6]

[1]Department of Gastroenterology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People's Republic of China; [2]Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, People's Republic of China; [3]Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, Shandong, People's Republic of China; [4]Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People's Republic of China; [5]Department of Gastrointestinal Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People's Republic of China; [6]Department of Neurosurgery, Shandong Province Qianfoshan Hospital of Shandong University, Jinan 250014, Shandong, People's Republic of China

*These authors contributed equally to this work

Correspondence: Lei Wang
Department of Gastrointestinal Surgery, Jinan Central Hospital Affiliated to Shandong University, 105 Jiefang Road, Jinan 250013, Shandong, People's Republic of China
Email wanglei999qq@163.com

Jie Lu
Department of Neurosurgery, Shandong Province Qianfoshan Hospital of Shandong University, 16766 Jingshi Road, Jinan 250014, Shandong, People's Republic of China
Email dr_peterluu@163.com

**Purpose:** The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients.

**Materials and methods:** One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before operation, then KRAS mutation status was analyzed through pathologically confirmed CRC samples. The association between tumor clinical characteristics and PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax), SUVmean, and metabolic tumor volume (MTV), and KRAS mutation status was analyzed using chi-squared tests, Mann–Whitney $U$ tests, and logistic regression analysis.

**Results:** The KRAS mutation type patients exhibited high MTV and high SUVmax using a threshold of 17.8 cm³ and 8.7 respectively and the predictive accuracy was 0.772 and 0.603 respectively. High MTV ($P$=0.001; 95% CI: 1.119–1.296) and high SUVmax ($P$=0.048; 95% CI: 0.564–0.985) were independent predictors for KRAS mutation status.

**Conclusion:** MTV and SUVmax were associated with KRAS mutation type in CRC patients. PET/CT metabolic parameters can be used for supplementing KRAS mutation status prediction in CRC patients.

**Keywords:** colorectal cancer, ¹⁸F-FDG PET/CT, SUVmax, SUVmean, MTV, KRAS mutation

## Introduction

Colorectal cancer (CRC) has high incidence and is the third most common cancer in the worldwide context.[1,2] Over the last 20 years, new molecular insights have indicated the mechanism of tumor initiation and progression for CRC. For instance, adenomatous polyposis coli gene mutation, KRAS gene activation, and P53 gene inhibition are closely related to carcinogenesis, progression, prognosis, and treatment decision of CRC.[3–6] Monoclonal antibody targeting EGFR has made significant breakthrough and great enrichment in the field of colorectal therapy. Nevertheless, KRAS mutation occurs in ~40% of CRC patients and studies have demonstrated that KRAS mutation always predicts a lack of responses to EGFR targeted therapies in metastatic CRC.[7–9]

¹⁸F-FDG PET/CT imaging is widely used for early diagnosis, staging, and judgment of recurrence and metastasis after surgery in CRC patients. Exploring the correlation between pretreatment images and genetic alteration is a challenging work to optimize the predictive value of KRAS mutation. CRYSTAL (chemotherapy and cetuximab in metastatic colorectal cancer) and OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) studies have shown that metastatic CRC patients with wild-type (WT) KRAS tumor can benefit from cetuximab treatment, whereas

the KRAS mutation type patients cannot achieve benefits.[10] Thus, a noninvasive imaging method to predict the KRAS mutation status, especially for patients who cannot undergo an invasive examination, is necessary and valuable. In addition, considering CRC is a heterogeneous disease, the specific location of tumor tissue may not be able to exactly reflect the KRAS mutation status of the entire tumor.[11] Several studies have explored the relationship between PET/CT imaging and KRAS mutation in CRC patients. Cho et al found KRAS mutation patients were inclined to have lung metastasis and had higher $^{18}$F-FDG uptake compared to WT KRAS in stage IV CRC patients.[12] Two clinical studies demonstrated that higher $^{18}$F-FDG uptake was associated with KRAS mutation in CRC patients.[13,14] One study indicated that the maximum standardized uptake value (SUVmax) for the primary tumor and tumor-to-liver ratio was higher in CRC patients with KRAS mutation. Furthermore, the relationship between different PET/CT metabolic parameters and KRAS mutation status is worth exploring.

In this study, we investigated clinical characteristics and PET/CT metabolic parameters that could potentially predict KRAS mutation status in a cohort of CRC patients and verified the predictive value via receiver operating characteristic (ROC) curve analysis.

## Materials and methods
### Patient population selection
After obtaining approval from the Ethics Review Board, 164 newly diagnosed CRC patients who underwent PET/CT examination before primary tumor resection from 2012 to 2017 were identified in this study. This retrospective study was approved by the Ethics Committee. All patients provided written informed consent and this study was conducted in accordance with the Declaration of Helsinki. All pathologically confirmed CRC patients accepted with further KRAS mutation status analysis. No patients received preoperative chemotherapy. The median age was 56 years (range: 29–86 years). Ninety-nine patients were men and 65 patients were women. Among them, most of the patients had pathological features, including moderate differentiation, nonmucinous adenocarcinoma, and full thickness invasive depth. Regional lymph node (RLD) metastasis and late stage patients accounted for the majority. All patients were suitable for accepting PET/CT examination. The clinical characteristics of the 164 patients are shown in Table 1. Patient clinical characteristics according to KRAS mutation status are shown in Table 2.

**Table 1** Patient clinical characteristics

| Characteristics | Number (%) |
| --- | --- |
| Patients, n | 164 |
| Age, years | |
|   Median (range) | 56 (29–86) |
| Gender | |
|   Male | 99 (60.4) |
|   Female | 65 (39.6) |
| Differentiation | |
|   Poor | 24 (14.6) |
|   Moderate | 125 (76.2) |
|   Well | 15 (9.2) |
| Histologic type | |
|   Nonmucinous adenocarcinoma | 140 (85.4) |
|   Mucinous adenocarcinoma | 19 (11.6) |
|   Signet-ring cell carcinoma | 5 (3.0) |
| Invasive depth | |
|   Superficial muscle | 5 (3.0) |
|   Deep muscle | 10 (6.1) |
|   Full thickness | 149 (90.9) |
| RLD metastasis | |
|   Positive | 107 (65.2) |
|   Negative | 57 (34.8) |
| Lymphovascular invasion | |
|   Positive | 88 (53.7) |
|   Negative | 76 (46.3) |
| Distant metastasis | |
|   Positive | 45 (27.4) |
|   Negative | 119 (72.6) |
| Stage, AJCC | |
|   I/II | 47 (28.7) |
|   III/IV | 117 (71.3) |
| KRAS mutation status | |
|   Mutation type | 72 (43.9) |
|   Wild-type | 92 (56.1) |
| SUVmax (mean±SD) | 12.1±6.9 |
| SUVmean (mean±SD) | 7.4±4.1 |
| MTV (mean±SD) | 22.7±17.0 |

**Abbreviations:** AJCC, American Joint Committee on Cancer; MTV, metabolic tumor volume; RLD, regional lymph node; SUVmax, maximum standardized uptake value.

## PET/CT imaging acquisition and analysis
All patients fasted for at least 6 hours before receiving PET/CT examination. Their blood glucose levels were then suitable for intravenous injection of $^{18}$F-FDG. The PET images were reconstructed by attenuation and iterative reconstruction, then multi-layered, multi-imaged, and merged with the CT images to ensure image clarity. This procedure was conducted by manufacturer review workstation (Xeleris™; GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). The SUVmax and SUVmean parameters of the primary tumor area were automatically captured and calculated. In our study, MTV was defined as the sum of the primary tumor metabolic volumes using a SUVmax of 2.5 as the threshold.[15,16]

**Table 2** Patient clinical characteristics according to KRAS mutation status

| Variables | Cases (N=164) | KRAS + (%) | KRAS − (%) | P-value |
|---|---|---|---|---|
| Age, years | | | | 0.580 |
|   >56 | 78 | 36 (46.1) | 42 (53.9) | |
|   ≤56 | 86 | 36 (41.9) | 50 (58.1) | |
| Gender | | | | 0.417 |
|   Male | 99 | 52 (46.0) | 61 (54.0) | |
|   Female | 65 | 20 (39.2) | 31 (60.8) | |
| Differentiation | | | | 0.055 |
|   Poor | 24 | 10 (41.7) | 14 (58.3) | |
|   Moderate | 125 | 51 (40.8) | 74 (59.2) | |
|   Well | 15 | 11 (73.3) | 4 (26.7) | |
| Histologic type | | | | 0.534 |
|   Nonmucinous adenocarcinoma | 140 | 63 (45.0) | 77 (55.0) | |
|   Mucinous adenocarcinoma | 19 | 8 (42.1) | 11 (57.9) | |
|   Signet-ring cell carcinoma | 5 | 1 (20.0) | 4 (80.0) | |
| Invasive depth | | | | 0.508 |
|   Superficial muscle | 5 | 2 (40.0) | 3 (60.0) | |
|   Deep muscle | 10 | 4 (40.0) | 6 (60.0) | |
|   Full thickness | 149 | 83 (55.7) | 66 (44.3) | |
| RLD metastasis | | | | 0.504 |
|   Positive | 107 | 49 (45.8) | 58 (54.2) | |
|   Negative | 57 | 23 (40.3) | 34 (59.7) | |
| Lymphovascular invasion | | | | 0.066 |
|   Positive | 88 | 45 (51.1) | 43 (48.9) | |
|   Negative | 76 | 28 (36.8) | 48 (63.2) | |
| Distant metastasis | | | | 0.028 |
|   Positive | 45 | 26 (57.8) | 19 (42.2) | |
|   Negative | 119 | 46 (38.7) | 73 (61.3) | |
| Stage, AJCC | | | | 0.206 |
|   I/II | 47 | 17 (36.2) | 30 (63.8) | |
|   III/IV | 117 | 55 (47.0) | 62 (53.0) | |
| SUVmax (mean±SD) | 164 | 13.5±7.8 | 11.0±5.9 | 0.023 |
| SUVmean (mean±SD) | 164 | 8.2±4.6 | 6.9±3.6 | 0.059 |
| MTV (mean±SD) | 164 | 30.8±21.3 | 16.3±8.4 | 0.001 |

**Abbreviations:** AJCC, American Joint Committee on Cancer; MTV, metabolic tumor volume; RLD, regional lymph node; SUVmax, maximum standardized uptake value.

## KRAS mutation analysis

Pathological samples were obtained following tumor resection for analyzing the KRAS mutation status. Pathologists selected the tumor area in tissue blocks and extracted DNA from formalin-fixed, paraffin-embedded tumor tissue slides using FFPE Tissue Kits and DNeasy Blood & Tissue Kits. Polymerase chain reaction was used to amplify the KRAS exon 2 gene and the ABI 3730XL automated DNA analyzer was used to analyze KRAS exon 2 gene using direct sequencing.

## Statistical analyses

The categorical variables including clinical characteristics between two or three groups were tested using chi-squared tests. The continuous covariates were expressed as mean ± SD. The differentiations between such PET/CT metabolic parameters and KRAS mutation status were analyzed by Mann-Whitney *U* test. We used ROC analysis to obtain PET/CT metabolic parameters' cutoff values to predict KRAS mutation status. In addition, the multivariate logistic regression analysis was used to confirm the predictive values of PET metabolic parameters for the KRAS mutation status. It is widely known that the area under the ROC curve (AUC) is defined as the predictive value and when the AUC is not <0.7 it represents a good discrimination value.[17] All analyses were two-sided and $P<0.05$ was considered statistically significant. Statistical analyses were performed using SPSS Statistics version 20.0 (IBM Corporation, Armonk, NY, USA).

## Results
## Patient clinical characteristics

We enrolled 164 newly diagnosed CRC patients who underwent PET/CT examination before primary tumor resection and pathological samples were obtained to examine the

KRAS mutation status. Moderate differentiation (n=125, 76.2%), nonmucinous adenocarcinoma (n=140, 85.4%), and full thickness invasive depth (n=140, 90.9%) account for the vast majority of patients. In addition, 107 patients (65.2%) had RLD metastasis and 117 patients (71.3%) were at stage III/IV. Among the 164 patients, 72 patients had KRAS exon 2 gene mutation type and the mutation rate was 43.9%. The main mutation subtypes were G12D (n=18, 25.0%), G12V (n=17, 23.6%), G13D (n=15, 20.8%), and G12A (n=11, 15.3%). In addition, seven patients (9.7%) had G12S mutation and four patients (5.6%) had G12C mutation. The clinical characteristics of the 164 patients are shown in Table 1. Patient clinical characteristics according to KRAS mutation status are shown in Table 2.

## Clinical characteristics and KRAS mutation

Patients at diagnosis had significant correlation between KRAS mutation status and distant metastasis ($P$=0.028). In addition, patients with KRAS mutation status showed a higher level of differentiation ($P$=0.055) and higher SUVmean ($P$=0.059) than patients with WT KRAS, although the differences were not significant. Other clinical characteristics, including gender, histologic type, invasive depth, RLD metastasis, and stages, were not significantly different between the two groups of patients with KRAS mutation status (Table 2).

## Association between PET metabolic parameters and KRAS mutation

From Table 2, we found that patients with KRAS mutation status had significantly higher SUVmax (13.5±7.8 vs 11.0±5.9, $P$=0.023) and MTV (30.8±21.3 vs 16.3±8.4, $P$=0.001) than those with WT KRAS (Table 2). The quantitative difference of SUVmax and MTV between the two groups of patients with KRAS mutation status are shown in Figure 1. No significant difference of SUVmean was found in the two groups of patients with KRAS mutation status.

## Predictive value of SUVmax and MTV for KRAS mutation status

In univariate analysis, KRAS mutation status was significantly correlated with distant metastasis ($P$=0.029), high SUVmax ($P$=0.026), high SUVmean ($P$=0.049), and high MTV ($P$=0.001). We incorporated these factors into multivariate analyses, and it was revealed that high SUVmax ($P$=0.048) and high MTV ($P$=0.001) were independent predictors for KRAS mutation status (Table 3). ROC curve analysis was performed: the AUC for SUVmax was 0.603 (95% CI: 0.516–0.691). A cutoff value of 8.7 was used, which maximized specificity and sensitivity (43.5% and 72.2%, respectively), then the patients were divided into groups of low or high SUVmax. The AUC for MTV was 0.772 (95% CI: 0.698–0.845). A cutoff value of 17.8 was used, which maximizes specificity and sensitivity (69.6% and 76.4%, respectively) then the patients were divided into groups of low or high MTV (Figure 2). Furthermore, KRAS mutation status was more common in patients with high MTV and high SUVmax than in those with low MTV (66.3% vs 21.0%, $P$=0.001) and low SUVmax (53.7% vs 37.1%, $P$=0.035).

## Discussion

KRAS mutation occurs in ~40% of CRC patients and studies have demonstrated that KRAS mutation always predicts a lack of responses to EGFR targeted therapies in metastatic



**Figure 1** Analysis of SUVmax and MTV according to KRAS mutation status.
**Notes:** (**A**) SUVmax was significantly higher in patients with KRAS mutation than in those with WT KRAS ($P$=0.023; Mann–Whitney $U$ test). (**B**) MTV was significantly higher in patients with KRAS mutation than in those with WT KRAS ($P$=0.001; Mann–Whitney $U$ test).
**Abbreviations:** MTV, metabolic tumor volume; SUVmax, maximum standardized uptake value; WT, wild-type.

**Table 3** Univariate and multivariate regression analyses for predicting KRAS mutation status

| Variables | Univariate P-value | OR | 95% CI | Multivariate P-value | OR | 95% CI |
|---|---|---|---|---|---|---|
| Age | 0.968 | 1.020 | 0.453–1.558 | | | |
| Gender | 0.725 | 0.846 | 0.503–1.778 | | | |
| Differentiation | 0.057 | 0.275 | 0.883–3.305 | | | |
| Histologic type | 0.732 | 1.167 | 0.348–1.451 | | | |
| Invasive depth | 0.608 | 0.560 | 0.524–2.410 | | | |
| RLD metastasis | 0.148 | 0.676 | 0.651–2.396 | | | |
| Lymphovascular invasion | 0.066 | 1.123 | 0.917–3.206 | | | |
| Distant metastasis | 0.029 | 2.172 | 1.081–4.361 | 0.240 | 1.645 | 0.718–3.769 |
| Stage | 0.208 | 1.565 | 0.780–3.143 | | | |
| SUVmax | 0.026 | 1.055 | 1.006–1.106 | 0.048 | 0.758 | 0.564–0.985 |
| SUVmean | 0.049 | 1.081 | 1.000–1.169 | 0.597 | 1.120 | 0.737–1.702 |
| MTV | 0.001 | 1.097 | 1.055–1.139 | 0.001 | 1.204 | 1.119–1.296 |

**Abbreviations:** MTV, metabolic tumor volume; RLD, regional lymph node; SUVmax, maximum standardized uptake value.

CRC.[7–9] Thus, for patients who cannot undergo an invasive examination, a noninvasive imaging method to predict the KRAS mutation status is necessary and valuable. In addition, considering CRC is a heterogeneous disease, specific location of tumor tissue may not be able to exactly reflect the KRAS mutation status of the entire tumor. In our study, we demonstrated PET/CT metabolic parameters such as MTV (P=0.001) and SUVmax (P=0.048) were independent predictors for KRAS mutation. MTV with the threshold of 17.8 cm³ achieved higher accuracy in predicting KRAS mutation than SUVmax with a threshold of 8.7 through ROC analysis (0.772 vs 0.603). However, SUVmean (P=0.597) did not show a predictive value for KRAS mutation status.



**KRAS**

**Figure 2** The prediction models consist of two metabolic parameters.
**Abbreviations:** AUC, area under the curve; MTV, metabolic tumor volume; SUVmax, maximum standardized uptake value.

PET/CT imaging involves the quantitative information of tumor depending on ¹⁸F-FDG uptake, which is superior to CT or MRI that rely on the doctor's subjective judgement. Several studies have explored the underlying mechanism of the relationship between glucose accumulation and KRAS mutation status. Yun et al studied the transcriptomes of paired CRC cell lines and found GLUT1 which encodes glucose transporter-1 was upregulated in KRAS or BRAF mutations CRC cell lines. Therefore the KRAS mutant cells exhibited enhanced glucose uptake, whereas the WT cells were subjected to a low glucose environment.[18] Sasaki et al also explored the correlation between the KRAS mutation and glucose accumulation in 283 non-small-cell lung cancer samples and demonstrated GLUT1, as the most common glucose transporter in cells, was highly expressed in cells with KRAS mutation status.[19] All these observations may explain the phenomenon that tumors with KRAS mutation status always had glucose accumulation. Thus, PET/CT metabolic parameters may be theoretically an ideal predictor for KRAS mutation status. Kawada et al conducted a study to verify whether FDG accumulation is associated with KRAS mutation status and its predictive value of KRAS status in metastatic CRC patients.[13] They demonstrated that SUVmax remained significantly associated with KRAS mutations and that it was an ideal predictor of KRAS status with an accuracy of 71.4%.[12] In addition, Lee et al also depicted SUVmax and SUVpeak to be significantly associated with KRAS mutation.[20] However, they did not explore whether these metabolic parameters were predictors for KRAS status. Iwamoto et al investigated the mechanisms that mutated KRAS status increased FDG accumulation and found that upregulation of GLUT1 and additive effect of hypoxia-inducible factor 1α (HIF-1α) in hypoxic lesions could cause FDG accumulation in CRC with KRAS mutation status.[21]

Several studies have reported the correlation between KRAS status and clinical outcomes after topical treatment of CRC liver metastases (CLM).[22–25] Shady et al[22] evaluated the prognostic value of KRAS mutation in patients with CLM who underwent percutaneous radiofrequency ablation (RFA) and found KRAS mutation was a predictor of poor overall survival (OS) ($P$=0.016), new liver metastases ($P$=0.037), and peritoneal metastases ($P$=0.015). Similar results were also demonstrated in two other studies. Calandri et al[23] found 3-year local tumour progression-free survival rates of KRAS mutant subgroups were significantly worse than WT KRAS subgroups ($P$<0.001 and $P$=0.006). The same result was also verified in the research by Odisio et al, with a $P$-value of 0.001.[24] In addition to RFA, Yttrium-90 radioembolization therapy is also an important topical treatment option for unresectable CLM. KRAS mutation was verified to be an independent prognostic factor for poor OS in patients with CLM treated with Yttrium-90 radioembolization therapy.[25] Therefore, KRAS status is important for the management of the treatment of patients with CLM.

We explored the association between KRAS mutation status and different clinical characteristics in our study, such as sex, differentiation, histologic type, invasive depth, RLD metastasis, distant metastasis, and stage. We did not find significant association between these characteristics. Nevertheless, the KRAS mutation group was found to have tumors with distant metastasis ($P$=0.028). Our study demonstrated that a high MTV was significantly associated with KRAS mutation ($P$=0.001). A high SUVmax was also a good predictor for KRAS mutation ($P$=0.048). SUVmean was not found to be associated with KRAS mutation ($P$=0.597). Our study provided evidence that PET/CT metabolic parameters have an important role in the noninvasive prediction of KRAS mutation status. SUVmax was a semiquantitative parameter that could vary with different factors, such as PET scanners, plasma glucose level fasting duration, and region of interest parameters. However, MTV was a quantitative parameter that reflect the glucose uptake of the entire tumor. Thus, MTV was superior to SUVmax in predicting gene mutation status.[26,27] Several studies also demonstrated that MTV was an important factor in predicting the clinical outcomes in several kinds of tumors.[26,28–30]

## Limitations

The limitation of this study was its retrospective character which existed inevitable bias. In addition, considering that WT KRAS left hemicolon cancer and WT KRAS right hemicolon cancer have different responses to cetuximab,

there may be a discrepancy in biological behavior between colon cancers at different primary sites. Thus, it is necessary to analyze the association between PET/CT parameters and KRAS mutation status in left and right hemicolon cancer, respectively. PET/CT parameters were also found to be associated with neoadjuvant chemoradiotherapy response in patients with locally advanced rectal tumor.[31,32] Thus, monitoring the association between the quantitative changes of PET/CT parameters and KRAS mutation status is necessary. Regrettably, we did not analyze it due to limited sample size. Furthermore, comprehensive analysis of various metabolic parameter thresholds may be a good choice in further studies. Also, future studies should use standardized protocols for ^{18}F-FDG PET acquisition and correction of the partial volume effect or false-positive PET findings[33] to augment its predictive value.

## Conclusion

PET/CT metabolic parameters can be used for KRAS mutation status prediction in CRC patients. In our study, we found that KRAS mutation status was associated with high MTV and high SUVmax using a threshold of 17.8 cm³ and 8.7, respectively, and the predictive accuracy was 0.772 and 0.603, respectively.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. *Int J Cancer*. 1993;54(4):594–606.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. *CA Cancer J Clin*. 1997;47(1):5–27.
3. Leslie A, Pratt NR, Gillespie K, et al. Mutations of APC, K-Ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. *Cancer Res*. 2003;63(15):4656–4661.
4. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC. The prognostic significance of K-Ras, p53, and APC mutations in colorectal carcinoma. *Gut*. 2005;54(9):1283–1286.
5. Lièvre A, Bachet JB, Boige V, et al. *KRAS* mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol*. 2008;26(3):374–379.
6. Westra JL, Schaapveld M, Hollema H, et al. Determination of *TP53* mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. *J Clin Oncol*. 2005;23(24):5635–5643.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. *K-ras* mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med*. 2008;359(17):1757–1765.
8. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. *N Engl J Med*. 2007;357(20):2040–2048.
9. Amado RG, Wolf M, Peeters M, et al. Wild-type *KRAS* is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2008;26(10):1626–1634.

10. Bokemeyer C, van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the crystal and OPUS randomised clinical trials. *Eur J Cancer*. 2012;48(10):1466–1475.

11. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin Cancer Res*. 2010; 16(3):790–799.

12. Cho A, Jo K, Hwang SH, et al. Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. *Abdom Radiol*. 2017; 42(6):1621–1626.

13. Kawada K, Nakamoto Y, Kawada M, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. *Clin Cancer Res*. 2012;18(6):1696–1703.

14. Chen SW, Chiang HC, Chen WT, et al. Correlation between PET/CT parameters and KRAS expression in colorectal cancer. *Clin Nucl Med*. 2014;39(8):685–689.

15. Meng X, Sun X, Mu D, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2012;82(2):960–966.

16. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. *Nature*. 1987;327(6120):298–303.

17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. 1982;143(1):29–36.

18. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science*. 2009;325(5947):1555–1559.

19. Sasaki H, Shitara M, Yokota K, et al. Overexpression of GLUT1 correlates with KRAS mutations in lung carcinomas. *Mol Med Rep*. 2012; 5(3):599–602.

20. Lee JH, Kang J, Baik SH, et al. Relationship between 18F-fluorodeoxyglucose uptake and V-Ki-Ras2 Kirsten rat sarcoma viral oncogene homolog mutation in colorectal cancer patients. *Medicine (Baltimore)*. 2016;95(1):e2236.

21. Iwamoto M, Kawada K, Nakamoto Y, et al. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. *J Nucl Med*. 2014;55(12):2038–2044.

22. Shady W, Petre EN, Vakiani E, et al. KRAS mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. *Oncotarget*. 2017;8(39):66117–66127.

23. Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: interaction of ablation margins and ras mutation profiling on local tumour progression-free survival. *Eur Radiol*. 2018;28(7): 2727–2734.

24. Odisio BC, Yamashita S, Huang SY, et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to *RAS* mutation status. *Br J Surg*. 2017;104(6):760–768.

25. Lahti SJ, Xing M, Zhang D, et al. KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. *J Vasc Interv Radiol*. 2015;26(8):1102–1111.

26. Ikeno Y, Seo S, Iwaisako K, et al. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis. *J Transl Med*. 2018;16(1):95.

27. Liu A, Han A, Zhu H, et al. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. *Oncotarget*. 2017;8(20): 33736–33744.

28. Chung HW, Lee KY, Kim HJ, Kim WS, So Y. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. *J Cancer Res Clin Oncol*. 2014; 140(1):89–98.

29. Yoo SW, Kim J, Chong A, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. *Nucl Med Mol Imaging*. 2012;46(4): 286–293.

30. Ho TY, Chou PC, Yang CT, Tsang NM, Yen TC. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma. *Clin Nucl Med*. 2015;40(6):e295–e299.

31. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. *Eur J Nucl Med Mol Imaging*. 2013;40(6):853–864.

32. Maffione AM, Ferretti A, Chondrogiannis S, et al. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria. *Clin Nucl Med*. 2013;38(10):795–797.

33. Maffione AM, Chondrogiannis S, Marzola MC, et al. Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer. *Clin Nucl Med*. 2014;39(3):e215–e219.